Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEN-181
- Development stage
- Unknown
- Lead developer
- Dendright
- Modality
- Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
**DEN-181** is an investigational, antigen-specific tolerizing immunotherapy for anti-citrullinated protein antibody-positive rheumatoid arthritis. It is a subcutaneous liposomal fixed-dose product containing a type II collagen 259-273 self-peptide and calcitriol. The collagen peptide is intended to promote antigen-specific regulation of autoreactive T-cell responses, while calcitriol provides tolerogenic dendritic-cell conditioning through vitamin D receptor signaling and NF-kappa-B pathway suppression. In a randomized placebo-controlled Phase I study in HLA-DRB1*04:01- or *01:01-positive ACPA-positive rheumatoid arthritis patients receiving methotrexate, single-dose DEN-181 was generally well tolerated and produced exploratory antigen-specific immunomodulatory signals. ([anzctr.org.au](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373425))
- Other names
- Curcusome-RACurcusomeRA
02
Targets
Type II collagen-specific T-cell receptorVDR (Vitamin D receptor)MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on DEN-181.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEN-181.